AIM: Sodium glucose cotransporter 2 (SGLT2) inhibitors prevent cardiovascular complications in type 2 diabetes. We aimed to study whether they have similar effects in women and men. METHODS: We summarised the effects of SGLT2 compared to placebo on vascular and safety outcomes by sex. We included patients with type 2 diabetes enrolled in the EMPA-REG OUTCOME, CANVAS Program, DECLARE TIMI-58 and CREDENCE trials. RESULTS: There were no sex differences in the risk ratios, SGLT2 versus control, for vascular efficacy outcomes or death (all p interaction ≥ 0.12) with clear protection against major adverse cardiovascular events, heart failure, vascular death and total mortality. SGLT2 inhibitor treatment was also associated with comparable relative risks in women and men for the safety outcomes of amputation, fracture, genital infection and urinary tract infection (all p interaction ≥ 0.17). CONCLUSION: SGLT2 inhibition provided comparable protection against vascular risks and death, and similar risks of serious adverse events, for women and men. This article is protected by copyright. All rights reserved.